Responses
Regular and young investigator award abstracts
Clinical trials in progress
364 A personal neoantigen vaccine NEO-PV-01 in combination with chemotherapy and pembrolizumab induces broad de novo immune responses in first line, non-squamous NSCLC
Compose a Response to This Article
Other responses
No responses have been published for this article.
